Dynavax Technologies | Brutto Fortjeneste På Salg

Gross Profit On Sales Endring Dato
AbbVie USD 8.22B 1.35B 2024-03
Adma Biologics USD 39.11M 8.02M 2024-03
Amgen USD 4.25B 837M 2024-03
AstraZeneca USD 10.46B 718M 2024-03
Biogen USD 1.75B 19.7M 2024-03
BioMarin Pharmaceutical USD 523.65M 12.92M 2024-03
Bristol-Myers Squibb USD 8.93B 163M 2024-03
Dynavax Technologies USD 39.82M 7.08M 2024-03
Gilead Sciences USD 5.13B 370M 2024-03
Glaxosmithkline GBP 5.39B 326M 2024-03
Merck USD 12.24B 945M 2024-03
Neurocrine Biosciences USD 507.8M 20.2M 2024-03
Novartis USD 9.02B 235M 2024-03
Pfizer USD 11.5B 3.92B 2024-03
Regeneron Pharmaceuticals USD 2.71B 206.1M 2024-03
Roche Holding CHF 22.16B 123M 2023-06
Sarepta Therapeutics USD 362.9M 68.11M 2024-03
TG Therapeutics USD 58.03M 21.92M 2024-03
Vertex Pharmaceuticals USD 2.35B 183.2M 2024-03



Dynavax Technologies Brutto Fortjeneste På Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Jun 2024.